Overview

This trial is active, not recruiting.

Condition brain neoplasms
Treatments irradiation, radiosurgery
Phase phase 2
Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator University of Pittsburgh
Start date November 1994
Trial size 40 participants
Trial identifier NCT00004659, 199/11858, UPPUH-9511117

Summary

OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function.

II. Examine survival, clinical outcome, and local tumor imaging response in these patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Primary purpose treatment

Eligibility Criteria

Male or female participants of any age.

- Multiple newly diagnosed brain tumors - Histologic confirmation of carcinoma at primary or metastatic site - Tumors less than 25 mm mean diameter and more than 5 mm from optic chiasm - No more than 4 tumors on magnetic resonance imaging - Systemic disease controlled - Neurologic function preserved - Radiographic staging within 2 months of randomization required - Performance status: Karnofsky 70%-100%

Additional Information

Description PROTOCOL OUTLINE: This is a randomized study. Tumor size and number are confirmed prior to randomization. Patients are stratified by participating institution. Patients are randomly assigned to 1 of 2 treatment groups. One group is treated with fractionated whole-brain irradiation using megavoltage equipment. The second group receives stereotactic radiosurgery plus fractionated whole-brain radiotherapy. Stereotactic radiosurgery involves irradiation of all tumors to the margins on stereotactic computerized tomography or magnetic resonance imaging. Either treatment may be administered first; the second treatment begins within 1 month of the first. Concurrent anticonvulsants and steroids are allowed. Patients are followed for change in size and number of tumors at 1, 3, and 6 months; follow-up clinical exams are performed at least every 2 months.
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by Office of Rare Diseases (ORD).